Ensuring high standards for the delivery of NIPT world‐wide: Development of an international external quality assessment scheme

To ensure accurate and appropriate reporting of non‐invasive prenatal testing (NIPT) results, the standard of testing should be measured and monitored by participation in external quality assessment (EQA) schemes. The findings from international pilot EQAs for NIPT for the common trisomies are presented.

[1]  S. Patton,et al.  Recommended practice for laboratory reporting of non‐invasive prenatal testing of trisomies 13, 18 and 21: a consensus opinion , 2017, Prenatal diagnosis.

[2]  F. S. Jørgensen,et al.  Discordant non‐invasive prenatal testing (NIPT) – a systematic review , 2017, Prenatal diagnosis.

[3]  D. Oepkes,et al.  Trial by Dutch laboratories for evaluation of non‐invasive prenatal testing. Part II—women's perspectives† , 2016, Prenatal diagnosis.

[4]  D. Oepkes,et al.  Trial by Dutch laboratories for evaluation of non‐invasive prenatal testing. Part I—clinical impact , 2016, Prenatal diagnosis.

[5]  M. Watson,et al.  Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[6]  L. Chitty,et al.  Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units , 2016, British Medical Journal.

[7]  Yanxi Han,et al.  External Quality Assessment for Detection of Fetal Trisomy 21, 18, and 13 by Massively Parallel Sequencing in Clinical Laboratories. , 2016, The Journal of molecular diagnostics : JMD.

[8]  Aileen Clarke,et al.  Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis , 2016, BMJ Open.

[9]  S. Chandrasekharan,et al.  Global perspectives on clinical adoption of NIPT , 2015, Prenatal diagnosis.

[10]  K. Nicolaides,et al.  Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: updated meta‐analysis , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[11]  C. Strom,et al.  Discordant noninvasive prenatal testing and cytogenetic results: a study of 109 consecutive cases , 2014, Genetics in Medicine.

[12]  Borut Peterlin,et al.  Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic) , 2013, European Journal of Human Genetics.

[13]  D. Cram,et al.  Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. , 2014, Clinical chemistry.

[14]  A. Oliphant,et al.  Gestational age and maternal weight effects on fetal cell‐free DNA in maternal plasma , 2013, Prenatal diagnosis.

[15]  K. Nicolaides,et al.  Fetal fraction in maternal plasma cell‐free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[16]  A. Barrett,et al.  Implementing Prenatal Diagnosis Based on Cell-Free Fetal DNA: Accurate Identification of Factors Affecting Fetal DNA Yield , 2011, PloS one.

[17]  D. Maddocks,et al.  Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast , 2007, Prenatal diagnosis.

[18]  T K Lau,et al.  Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. , 1998, American journal of human genetics.